Associations Between HLA-DRB10102, HLA-B5801, and Hepatotoxicity During Initiation of Nevirapine-Containing Regimens in South Africa

被引：40

作者：

Phillips, Elizabeth ^{[1
,2
,3
,4
]}

Bartlett, John A. ^{[5
]}

Sanne, Ian ^{[6
]}

Lederman, Michael M. ^{[7
]}

Hinkle, John ^{[8
]}

Rousseau, Franck ^{[9
]}

Dunn, David ^{[1
]}

Pavlos, Rebecca ^{[1
]}

James, Ian ^{[1
]}

Mallal, Simon A. ^{[1
,2
]}

Haas, David W. ^{[10
,11
,12
,13
,14
]}

机构：

[1] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA 6150, Australia

[2] Royal Perth Hosp, Perth, WA, Australia

[3] Sir Charles Gairdner Hosp, Perth, WA, Australia

[4] Univ Western Australia, Perth, WA 6009, Australia

[5] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA

[6] Univ Witwatersrand, Dept Med, ZA-2001 Johannesburg, South Africa

[7] Case Western Reserve Univ, Cleveland, OH 44106 USA

[8] EarlyPhase Sci Inc, Cary, NC USA

[9] Tranzyme Pharma, Durham, NC USA

[10] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA

[11] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA

[12] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA

[13] Vanderbilt Univ, Sch Med, Dept Microbiol, Nashville, TN 37212 USA

[14] Vanderbilt Univ, Sch Med, Dept Immunol, Nashville, TN 37212 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2013年 / 62卷 / 02期

关键词：

HYPERSENSITIVITY; ALLELE;

D O I：

10.1097/QAI.0b013e31827ca50f

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：E55 / E57

页数：3

共 9 条

[1] HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients
Chantarangsu, Soranun
Mushiroda, Taisei
Mahasirimongkol, Surakameth
Kiertiburanakul, Sasisopin
Sungkanuparph, Somnuek
Manosuthi, Weerawat
Tantisiriwat, Woraphot
Charoenyingwattana, Angkana
Sura, Thanyachai
Chantratita, Wasun
Nakamura, Yusuke
[J]. PHARMACOGENETICS AND GENOMICS, 2009, 19 (02) : 139 - 146
[2] HLA-Cw8 primarily associated with hypersensitivity to nevirapine
Gatanaga, Hiroyuki
Yazaki, Hirohisa
Tanuma, Junko
Honda, Miwako
Genka, Ikumi
Teruya, Katsuji
Tachikawa, Natsuo
Kikuchi, Yoshirni
Oka, Shinichi
[J]. AIDS, 2007, 21 (02) : 264 - 265
[3] Haas DW, 2006, J INFECT DIS, V43, P783
[4] HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, SL
Chung, WH
Liou, LB
Chu, CC
Lin, M
Huang, HP
Lin, YL
Lan, JL
Yang, LC
Hong, HS
Chen, MJ
Lai, PC
Wu, MS
Chu, CY
Wang, KH
Chen, CH
Fann, CSJ
Wu, JY
Chen, YT
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (11) : 4134 - 4139
[5] HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients
Littera, Roberto
Carcassi, Carlo
Masala, Alessandro
Piano, Paola
Serra, Paolo
Ortu, Francesco
Corso, Nicoletta
Casula, Basilia
La Nasa, Giorgio
Contu, Licinio
Manconi, Paolo Emilio
[J]. AIDS, 2006, 20 (12) : 1621 - 1626
[6] Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
Mallal, S
Nolan, D
Witt, C
Masel, G
Martin, AM
Moore, C
Sayer, D
Castley, A
Mamotte, C
Maxwell, D
James, I
Christiansen, FT
[J]. LANCET, 2002, 359 (9308) : 727 - 732
[7] Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts
Martin, AM
Nolan, D
James, I
Cameron, P
Keller, J
Moore, C
Phillips, E
Christiansen, FT
Mallal, S
[J]. AIDS, 2005, 19 (01) : 97 - 99
[8] Phillips E, 2011, P 51 INT C ANT AG CH
[9] Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent
Yuan, Jing
Guo, Sheng
Hall, David
Cammett, Anna M.
Jayadev, Supriya
Distel, Manuel
Storfer, Stephen
Huang, Zimei
Mootsikapun, Piroon
Ruxrungtham, Kiat
Podzamczer, Daniel
Haas, David W.
[J]. AIDS, 2011, 25 (10) : 1271 - 1280

← 1 →

Associations Between HLA-DRB1*0102, HLA-B*5801, and Hepatotoxicity During Initiation of Nevirapine-Containing Regimens in South Africa

Associations Between HLA-DRB10102, HLA-B5801, and Hepatotoxicity During Initiation of Nevirapine-Containing Regimens in South Africa